{
    "nctId": "NCT05790096",
    "briefTitle": "Effectiveness and Safety Study of Filgrastine\u00ae in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy",
    "officialTitle": "Phase 3 Randomized Clinical Effectiveness Study Clinical and Safety of Filgrastine\u00ae in Patients With Breast Cancer Treated With Myelotoxic Chemotherapy",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "frequency of grade 4 neutropenia in the first cycle of chemotherapy in the group of patients treated with Filgrastine\u00ae",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of the Free and Informed Consent Form by written;\n* Female sex;\n* Age between 18 and 75 years old;\n* Diagnosis of breast cancer confirmed by cytology or histopathology;\n* Disease in stages II or III, according to the classification tumor-node-metastasis (TNM);\n* Indication of chemotherapy with full dose of one of the regimens eligible;\n* Performance status of 0 or 1;\n* Appropriate body functions (absolute neutrophil count \\[CAN\\] \u22651,500/mm\u00b3; platelet count \u2265150,000/mm\u00b3; serum creatinine \u22641.2 mg/dL; bilirubin and transaminases \u22641.5 times the upper limit of normal).\n\nExclusion Criteria:\n\n* Previous use of chemotherapy;\n* Previous use of filgrastim;\n* Prediction of prophylactic or therapeutic use of antibiotics, antifungals or antivirals in the first cycle of chemotherapy;\n* Previous radiotherapy involving the pelvis or radiotherapy from any site within the last 6 weeks prior to randomization;\n* History of bone marrow transplantation (as a recipient);\n* Presence of other neoplasms;\n* Presence of severe co-morbidities;\n* Recent (\\<6 months) or planned participation in other studies clinical trials involving drugs of any nature or in studies of any form of intervention;\n* Known intolerance or allergy to any of the components the filgrastim formulations evaluated in the study;\n* Pregnancy or lactation (patients of childbearing potential must have a negative serological pregnancy test dated within 7 days prior to randomization).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}